Overview

Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage

Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To provide children dependent on total parenteral nutrition with Omegaven®, a fish oil-based intravenous lipid emulsion that may be less hepatotoxic than conventional, vegetable oil-based intravenous lipid emulsions, and that may therefore reduce the need for liver transplantation.
Details
Lead Sponsor:
Georgetown University